Artisan Partners Limited Partnership Makes New $115.92 Million Investment in Zoetis Inc. $ZTS

Artisan Partners Limited Partnership bought a new stake in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 743,302 shares of the company’s stock, valued at approximately $115,918,000. Artisan Partners Limited Partnership owned 0.17% of Zoetis at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nova Wealth Management Inc. purchased a new stake in Zoetis during the first quarter valued at about $25,000. 1248 Management LLC bought a new stake in shares of Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank purchased a new stake in shares of Zoetis during the 1st quarter valued at approximately $29,000. REAP Financial Group LLC lifted its stake in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC boosted its holdings in Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $116.96 on Thursday. The firm has a market capitalization of $51.54 billion, a P/E ratio of 20.13, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock’s 50-day simple moving average is $138.98 and its two-hundred day simple moving average is $150.66. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $181.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the company posted $1.58 EPS. The company’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 33.67%.

Analysts Set New Price Targets

Several research firms have issued reports on ZTS. Stifel Nicolaus dropped their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday. Morgan Stanley dropped their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, November 10th. BTIG Research reduced their target price on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.